C:\Program Files\Stnexp\Queries\10723961.str





chain nodes :
10 11 19
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
chain bonds :
7-11 8-10 9-19 11-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16 16-17
exact/norm bonds :
5-9 7-11 8-9 8-10 9-19 11-13
exact bonds :
4-7 7-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 12 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom

=>
Uploading C:\Program Files\Stnexp\Queries\10723961.str



chain nodes :
10 11 19
ring nodes :
1 2 3 4 5 6 7 8 9 12 13 14 15 16 17
chain bonds :
7-11 8-10 9-19 11-13
ring bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-9 7-8 8-9 12-13 12-17 13-14 14-15 15-16
16-17
exact/norm bonds :
5-9 7-11 8-9 8-10 9-19 11-13
exact bonds :
4-7 7-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 12-13 12-17 13-14 14-15 15-16 16-17
isolated ring systems :
containing 1 : 12 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 sss sam
SAMPLE SEARCH INITIATED 18:56:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      211 TO ITERATE

100.0% PROCESSED      211 ITERATIONS                                  5 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         3349 TO     5091
PROJECTED ANSWERS:               5 TO      234

L2             5 SEA SSS SAM L1

=> => s l1 sss ful
FULL SEARCH INITIATED 18:56:53 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4507 TO ITERATE

100.0% PROCESSED     4507 ITERATIONS                                 40 ANSWERS
SEARCH TIME: 00.00.01

L3            40 SEA SSS FUL L1

=> => s l3
L4           10 L3

=> d l4 1-10 bib,ab,hitstr
```

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:473360 CAPLUS
DN 141:33813
TI Pyrimidine and indolone derivative GAL3 galanin receptor antagonists for the treatment of affective disorders
IN Konkel, Michael J.; Blackburn, Thomas P.; Wetzel, John M.
PA USA
SO U.S. Pat. Appl. Publ., 147 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004110821	A1	20040610	US 2003-638242	20030807
PRAI US 2002-401885P	P	20020807		

OS MARPAT 141:33813

→ No ODP ✗ claims are distinct to *

AB The invention discloses pyrimidine and indolone derivs. which are selective antagonists for the GAL3 galanin receptor. The invention provides a method for treating a subject suffering from an affective disorder which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's affective disorder. The invention also provides a method for treating an affective disorder in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist. The invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. Compound preparation is included.

IT **445454-93-3P 445454-95-5P 445454-96-6P**
445454-97-7P 445454-98-8P 445454-99-9P
445455-00-5P 445455-02-7P 445455-03-8P
445455-04-9P 445455-05-0P 445455-06-1P
445455-24-3P 445455-25-4P 445455-29-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyrimidine and indolone derivative GAL3 galanin receptor antagonists for treatment of affective disorders)

RN 445454-93-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chloro-3-methylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-95-5 CAPLUS

CN 2H-Indol-2-one, 3-[(4-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-96-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-iodophenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-97-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-98-8 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-99-9 CAPLUS
CN 2H-Indol-2-one, 3-([1,1'-biphenyl]-4-ylimino)-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-00-5 CAPLUS
CN Benzoic acid, 3-[(Z)-[1,2-dihydro-2-oxo-1-(3-thienyl)-3H-indol-3-ylidene]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-02-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-phenoxyphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-03-8 CAPLUS
CN 2H-Indol-2-one, 3-[(4-bromophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-04-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-,
(3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-05-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methylphenyl)imino]-1-(3-thienyl)-,
(3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-06-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dichlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-24-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[3-(1-methylethyl)phenyl]imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-25-4 CAPLUS
CN 2H-Indol-2-one, 3-[(4-cyclohexylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-29-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[[3-(trifluoromethyl)phenyl]imino]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **445455-58-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(pyrimidine and indolone derivative GAL3 galanin receptor antagonists for treatment of affective disorders)
RN 445455-58-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


S
N
O
E
N
Me

L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:430628 CAPLUS
DN 141:1272
TI Use of indolone derivative GALR3 receptor antagonists for the treatment of depression and/or anxiety, and compounds useful in such methods
IN Konkel, Michael; Werzel, John M.; Talisman, Jamie
PA USA
SO U.S. Pat. Appl. Publ., 58 pp., Cont.-in-part of U.S. Ser. No. 214,873, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004102507	A1	20040527	US 2003-414660	20030416 ← No ODP
	US 2003078271	A1	20030424	US 2002-66175 Abn	20020131
	WO 2004093789	A2	20041104	WO 2004-US11698	20040415
	WO 2004093789	A3	20050224		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI	US 2001-265586P	P	20010131
	US 2002-66175	B2	20020131 ← Parent Applⁿ.
	US 2002-214873	B2	20020807
	US 2003-414660	A	20030416

OS MARPAT 141:1272
AB The invention discloses indolone derivs. which are antagonists for the GALR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. Compound preparation is included.
IT **445453-46-3P 445454-93-3P 445455-00-5P**
693779-08-7P 693779-09-8P 693779-10-1P
693779-11-2P 693779-12-3P 693779-14-5P
693779-15-6P 693779-16-7P 693779-17-8P
693779-18-9P 693779-34-9P 693779-36-1P
693779-37-2P 693779-39-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(indolone derivative GALR3 receptor antagonists for treatment of depression and anxiety)

RN 445453-46-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(3-thienyl)-3-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 445454-93-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chloro-3-methylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-00-5 CAPLUS
CN Benzoic acid, 3-[(Z)-[1,2-dihydro-2-oxo-1-(3-thienyl)-3H-indol-3-ylidene]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 693779-08-7 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)- (9CI)

(CA INDEX NAME)



RN 693779-09-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-iodophenyl)imino]-1-(3-thienyl)- (9CI)
(CA INDEX NAME)



RN 693779-10-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)- (9CI)
(CA INDEX NAME)



RN 693779-11-2 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)imino]-1,3-dihydro-1-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 693779-12-3 CAPLUS
CN 2H-Indol-2-one, 3-([1,1'-biphenyl]-4-ylimino)-1,3-dihydro-1-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 693779-14-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-phenoxyphenyl)imino]-1-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 693779-15-6 CAPLUS
CN 2H-Indol-2-one, 3-[(4-bromophenyl)imino]-1,3-dihydro-1-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 693779-16-7 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 693779-17-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methylphenyl)imino]-1-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 693779-18-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dichlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 693779-34-9 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chloro-3-methylphenyl)imino]-1,3-dihydro-1-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 693779-36-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[3-(1-methylethyl)phenyl]imino]-1-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 693779-37-2 CAPLUS
CN 2H-Indol-2-one, 3-[(4-cyclohexylphenyl)imino]-1,3-dihydro-1-(3-thienyl)- (9CI) (CA INDEX NAME)



RN 693779-39-4 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



IT **445455-58-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(indolone derivative GALR3 receptor antagonists for treatment of depression and anxiety)
RN 445455-58-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:392329 CAPLUS
DN 140:406818
TI Preparation of pyrimidine and indol-2-one derivatives as GAL3 receptor antagonists for the treatment of neuropathic pain
IN Blackburn, Thomas P.
PA USA
SO U.S. Pat. Appl. Publ., 140 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2004092570	A1	20040513	US 2003-637299 ←	20030807
PRAI US 2002-402035P	P	20020807		

No ODP X

OS MARPAT 140:406818

AB The title compds. I [wherein W = H, halo, CN, alkyl, or alkoxy; X = (un)substituted amino, piperidino, 4-oxopiperidino, or piperazino; Y = (un)substituted NH2, 2-isoquinolinyl, morpholino, benz[de]isoquinolinyl, etc.; R1 = bicyclic ring, (nor)adamantyl, cycloalkyl, (un)substituted (hetero)aryl, etc.; or pharmaceutically acceptable salts thereof] and II [wherein Y1-Y4 = independently H, (cyclo)alkyl, (cyclo)alkenyl, alkynyl, halo, NO2, N3, CN, alkoxy, acyl, carbamoyl, (hetero)aryl, etc.; A = (un)substituted (hetero)aryl(alkyl), oxocycloalkylalkyl, heterocyclyl, alkenyl, alkynyl, etc.; B = (un)substituted (hetero)aryl or tricyclic heteroaryl; or pharmaceutically acceptable salts thereof] were prepared as selective antagonists for the galanin 3 (GAL3) receptor for the treatment of neuropathic pain. Examples include general procedures for synthesis of the compds. I and II, as well as procedures and data for numerous bioassays. For instance, III was prepared and showed selectivity for the hGAL3 receptor compared to the hGAL1 and hGAL2 receptors with binding affinities of Ki = 28 nM, 442 nM, and 176 nM, resp. III also exhibited antagonist selectivity ratios >30 for serotonin receptors and several transporters vs. hGAL3. In addition, behavioral tests were performed on rats to assess the analgesic properties of another exemplified compound, 1-phenyl-3-[[3-(trifluoromethyl)phenyl]imino]-1,3-dihydro-2H-indol-2-one (IV). The behavioral data demonstrated that i.p. administration of 30 mg/kg of IV significantly attenuated specific pain-related behaviors in neuropathic rats, namely mech. allodynia, without significant contralateral effects.

Method claims only drawn to treating abnormality

IT **445453-46-3P 445454-93-3P 445454-95-5P**
445454-96-6P 445454-97-7P 445454-98-8P
445454-99-9P 445455-00-5P 445455-02-7P
445455-03-8P 445455-04-9P 445455-05-0P
445455-06-1P 445455-24-3P 445455-25-4P
445455-29-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine and indol-2-one derivs. as galanin GAL3 antagonists for treatment of neuropathic pain)

RN 445453-46-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(3-thienyl)-3-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 445454-93-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chloro-3-methylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-95-5 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-96-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-iodophenyl)imino]-1-(3-thienyl)-, (3Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-97-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-98-8 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-99-9 CAPLUS
CN 2H-Indol-2-one, 3-([1,1'-biphenyl]-4-ylimino)-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-00-5 CAPLUS
CN Benzoic acid, 3-[(Z)-[1,2-dihydro-2-oxo-1-(3-thienyl)-3H-indol-3-ylidene]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-02-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-phenoxyphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-03-8 CAPLUS
CN 2H-Indol-2-one, 3-[(4-bromophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-04-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-05-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methylphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-06-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dichlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-24-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[3-(1-methylethyl)phenyl]imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-25-4 CAPLUS
CN 2H-Indol-2-one, 3-[(4-cyclohexylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-29-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[[3-(trifluoromethyl)phenyl]imino]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **445455-58-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine and indol-2-one derivs. as galanin GAL3 antagonists for treatment of neuropathic pain)
RN 445455-58-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:354686 CAPLUS
DN 140:375075
TI Preparation of 1-(phenyl or 3-pyridyl)-3-(phenylimino)-2-indolones for the treatment of depression and/or anxiety
IN Konkel, Michael; Wetzel, John M.; Talisman, Jamie
PA USA
SO U.S. Pat. Appl. Publ., 30 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004082615	A1	20040429	US 2003-637971	20030807
	US 2005148635	A1	20050707	US 2005-68203	20050228
PRAI	US 2002-402025P	P	20020807		
	US 2003-637971	B1	20030807		

OS MARPAT 140:375075
AB This invention is directed to indolone derivs. (I) [Y1-Y4 = H, straight or branched C1-7 alkyl, mono- or polyfluoroalkyl, F, Cl, Br, iodo, NO2, cyano, OR3, OCOR3, NHCOR3, N(R3)2, CON(R3)2, CO2R3, aryl, heteroaryl or any two of Y1, Y2, Y3 and Y4 moieties present on adjacent carbon atoms can constitute a methylenedioxy group; R1 = H, straight or branched C1-7 alkyl, mono- or polyfluoroalkyl, F, Cl, Br, iodo, N3, cyano, OR3, CON(R3)2, CO2R3, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, heteroaryl; R2 = H, straight or branched C1-7 alkyl, mono- or polyfluoroalkyl, F, Cl, Br, iodo, N3, cyano, OR3, CON(R3)2, CO2R3, aryl, heteroaryl, C1-7 cycloalkyl or cycloalkenyl or any two R2 moieties present on adjacent carbon atoms can constitute, a methylenedioxy group or a difluoromethylenedioxy group or any two R2 moieties present on adjacent carbon atoms along with the adjacent carbon atom can constitute an aryl or a heteroaryl ring; R3 = H, straight or branched C1-7 alkyl, mono- or polyfluoroalkyl, C3-7 cycloalkyl, C5-7 cycloalkenyl, aryl, heteroaryl; R4 = H, F, Cl, Me] or pharmaceutically acceptable salts thereof are prepared These compds. are selective antagonists for the GalR3 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound I and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound I and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound I and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of the compound I effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist. Thus, 3-[(3,4-dichlorophenyl)imino]-1,3-dihydro-2H-indol-2-one was coupled with (4-methoxypyridin-5-yl)boronic acid in the presence of copper(II) acetate and Et3N in CH2Cl2 with stirring at room temperature overnight to give, after purification by preparative TLC, 96% 3-[(3,4-dichlorophenyl)imino]-1-(6-methoxy-3-pyridinyl)-1,3-dihydro-2H-indol-2-one (II). II in vitro showed selective binding to human GalR3 receptor with Ki of 15 nM.

IT **659726-71-3P**, 3-[(3,4-Dichlorophenyl)imino]-1-(6-methoxy-3-pyridinyl)-1,3-dihydro-2H-indol-2-one **659726-72-4P**, 5-Chloro-3-[(3,4-dichlorophenyl)imino]-1-(6-methoxy-3-pyridinyl)-1,3-dihydro-2H-indol-2-one **659726-79-1P**, 3-[(3-Trifluoromethylphenyl)imino]-1-(6-methoxy-3-pyridinyl)-1,3-dihydro-2H-indol-2-one **659727-02-3P 659727-04-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of (Ph or pyridyl)(phenylimino)indolones as selective antagonists for GalR3 receptor for treatment of depression and/or anxiety)

RN 659726-71-3 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dichlorophenyl)imino]-1,3-dihydro-1-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 659726-72-4 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[(3,4-dichlorophenyl)imino]-1,3-dihydro-1-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 659726-79-1 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(6-methoxy-3-pyridinyl)-3-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 659727-02-3 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[(3,4-dichlorophenyl)imino]-1-(1,6-dihydro-6-oxo-3-pyridinyl)-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 659727-04-5 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dichlorophenyl)imino]-1-(1,6-dihydro-6-oxo-3-pyridinyl)-1,3-dihydro- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:143102 CAPLUS
DN 140:181325
TI Preparation of 3-imino-2-indolones as selective antagonists for GalR3 receptor for the treatment of depression and/or anxiety
IN Konkel, Michael; Wetzel, John M.; Talisman, Jamie
PA Synaptic Pharmaceutical Corporation, USA
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004014854	A1	20040219	WO 2003-US24867	20030807

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-215374 A 20020807
OS MARPAT 140:181325
AB Title compds. I [Y1, Y2, Y3 and Y4 independently = H, alkyl, mono- or poly-fluoroalkyl, halo, NO2, CN, etc., and any two of Y1, Y2, Y3 and Y4 present on adjacent carbons can constitute a methylenedioxy group; R1 = H, alkyl, mono- or poly-fluoroalkyl, halo, NO2, CN, cycloalkyl, cycloalkenyl, etc., and any two of Y1, Y2, Y3 and Y4 present on adjacent carbons can constitute a methylenedioxy or difluoromethylenedioxy group; R2 = H, F, Cl, or Me; Ar = (un)substituted pyridin-3-yl or hydroxyphenyl group] and their pharmaceutically acceptable salts are prepared and disclosed as selective antagonists for the GalR3 receptor. Thus, e.g., II was prepared by reaction of 5-chloroisatin with 3,4-dichloroaniline to form an intermediate iminoindole derivative which was coupled with 2-methoxypyridine-5-boronic acid. I were evaluated for their binding ability to the GalR3 receptor and possessed Ki values ranging from 15-72 nM. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's depression and/or anxiety. This invention also provides a method of treating depression and/or anxiety in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GalR3 receptor antagonist.
IT **659726-71-3P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of iminoindolones as antidepressants and anxiolytics with selectivity for GalR3 receptor)

RN 659726-71-3 CAPLUS

CN 2H-Indol-2-one, 3-[(3,4-dichlorophenyl)imino]-1,3-dihydro-1-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



IT **659726-72-4P 659726-79-1P 659727-02-3P 659727-04-5P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of iminoindolones as antidepressants and anxiolytics with selectivity for GalR3 receptor)

RN 659726-72-4 CAPLUS

CN 2H-Indol-2-one, 5-chloro-3-[(3,4-dichlorophenyl)imino]-1,3-dihydro-1-(6-methoxy-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 659726-79-1 CAPLUS

CN 2H-Indol-2-one, 1,3-dihydro-1-(6-methoxy-3-pyridinyl)-3-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 659727-02-3 CAPLUS
CN 2H-Indol-2-one, 5-chloro-3-[(3,4-dichlorophenyl)imino]-1-(1,6-dihydro-6-oxo-3-pyridinyl)-1,3-dihydro- (9CI) (CA INDEX NAME)



RN 659727-04-5 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dichlorophenyl)imino]-1-(1,6-dihydro-6-oxo-3-pyridinyl)-1,3-dihydro- (9CI) (CA INDEX NAME)



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:142959 CAPLUS
DN 140:193081
TI Pyrimidine and indolone derivative GAL3 receptor antagonists, and preparation thereof, for the treatment of affective disorders
IN Konkel, Michael; Blackburn, Thomas P.; Wetzel, John M.
PA Synaptic Pharmaceutical Corporation, USA
SO PCT Int. Appl., 427 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004014376	A1	20040219	WO 2003-US25133	20030807

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-215346 A 20020807
OS MARPAT 140:193081
AB The invention discloses pyrimidine and indolone derivs. which are selective antagonists for the GAL3 receptor. The invention provides a method of treating a subject suffering from an affective disorder which comprises administering an amount of a compound of the invention effective to treat the subject's affective disorder. The invention also provides a method of treating an affective disorder in a subject which comprises administering a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist. The invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of. a compound of the invention and a pharmaceutically acceptable carrier. Preparation of compds. of the invention is described.
IT **445453-46-3P 445454-93-3P 445454-95-5P**
445454-96-6P 445454-98-8P 445454-99-9P
445455-00-5P 445455-02-7P 445455-03-8P
445455-04-9P 445455-05-0P 445455-06-1P
445455-24-3P 445455-25-4P 445455-29-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyrimidine and indolone derivative GAL3 antagonists for treatment of neuropathic pain)
RN 445453-46-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(3-thienyl)-3-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 445454-93-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chloro-3-methylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-95-5 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-96-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-iodophenyl)imino]-1-(3-thienyl)-, (3Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-98-8 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-99-9 CAPLUS
CN 2H-Indol-2-one, 3-([1,1'-biphenyl]-4-ylimino)-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-00-5 CAPLUS
CN Benzoic acid, 3-[(Z)-[1,2-dihydro-2-oxo-1-(3-thienyl)-3H-indol-3-ylidene]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-02-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-phenoxyphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-03-8 CAPLUS
CN 2H-Indol-2-one, 3-[(4-bromophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-04-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-05-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methylphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-06-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dichlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-24-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[3-(1-methylethyl)phenyl]imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-25-4 CAPLUS
CN 2H-Indol-2-one, 3-[(4-cyclohexylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-29-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[[3-(trifluoromethyl)phenyl]imino]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **445454-97-7P 445455-58-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(pyrimidine and indolone derivative GAL3 antagonists for treatment of neuropathic pain)
RN 445454-97-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-58-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2004:142904 CAPLUS
DN 140:193080
TI Pyrimidine and indolone derivative GAL3 antagonists for the treatment of neuropathic pain
IN Blackburn, Thomas
PA Synaptic Pharmaceutical Corporation, USA
SO PCT Int. Appl., 359 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004014307	A2	20040219	WO 2003-US24869	20030807
WO 2004014307	A3	20041229		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-215267 A 20020807
OS MARPAT 140:193080
AB This invention discloses pyrimidine and indolone derivs. which are selective antagonists for the GAL3 receptor and are useful for the treatment of neuropathic pain and other abnormalities. The invention also provides a method of treating a subject suffering from an abnormality which comprises administering to the subject an amount of a compound of the invention effective to treat the subject's abnormality. The invention also provides a method of treating an abnormality in a subject which comprises administering to the subject a composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a GAL3 receptor antagonist. Compound preparation is described.
IT **445453-46-3P 445454-93-3P 445454-95-5P**
445454-96-6P 445454-98-8P 445454-99-9P
445455-00-5P 445455-02-7P 445455-03-8P
445455-04-9P 445455-05-0P 445455-06-1P
445455-24-3P 445455-25-4P 445455-29-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyrimidine and indolone derivative GAL3 antagonists for treatment of neuropathic pain)
RN 445453-46-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(3-thienyl)-3-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 445454-93-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chloro-3-methylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-95-5 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-96-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-iodophenyl)imino]-1-(3-thienyl)-, (3Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-98-8 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-99-9 CAPLUS
CN 2H-Indol-2-one, 3-([1,1'-biphenyl]-4-ylimino)-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-00-5 CAPLUS
CN Benzoic acid, 3-[(Z)-[1,2-dihydro-2-oxo-1-(3-thienyl)-3H-indol-3-ylidene]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-02-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-phenoxyphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-03-8 CAPLUS
CN 2H-Indol-2-one, 3-[(4-bromophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-04-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-05-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methylphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-06-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dichlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-24-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[3-(1-methylethyl)phenyl]imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-25-4 CAPLUS
CN 2H-Indol-2-one, 3-[(4-cyclohexylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-29-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[[3-(trifluoromethyl)phenyl]imino]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **445454-97-7P 445455-58-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(pyrimidine and indolone derivative GAL3 antagonists for treatment of neuropathic pain)
RN 445454-97-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-58-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2003:319458 CAPLUS
DN 138:321291
TI Preparation of pyrimidine and indol-2-one derivatives as galanin GAL3 receptor antagonists for the treatment of depression and/or anxiety
IN Blackburn, Thomas P.; Konkel, Michael J.; Boteju, Lakmal W.; Talisman, Ian Jamie; Wetzel, John M.; Packiarajan, Mathivanan; Chen, Heidi; Jimenez, Hermo
PA USA
SO U.S. Pat. Appl. Publ., 265 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003078271	A1	20030424	US 2002-66175 Parent	20020131
	US 2004102507	A1	20040527	US 2003-414660	20030416
	US 2004127502	A1	20040701	US 2003-723961	20031126
PRAI	US 2001-265586P	P	20010131		
	US 2002-66175	B2	20020131		
	US 2002-214873	B2	20020807		

OS MARPAT 138:321291
AB Title compds. I [W = H, halo, CN, etc.; X = substituted NH2, (un)substituted piperidino, 4-oxopiperidino, piperazino; R1 = bicyclic ring, adamantyl, (hetero)aryl, etc.; Y = substituted NH2, (un)substituted 2-isoquinolinyl, morpholino, etc]. and analogs are selective antagonists for the GAL3 receptor and are useful in treating depression and/or anxiety are prepared Various general procedures for synthesis of I and biol. data, are given. E.g., exemplified compound I [W = H; X = piperidino; Y = N-cyclohexyl-N-methylamino; R1 = 4-MeC6H4] showed Ki of 35 nM against GalR3 receptor binding vs. Ki of 668 nM and Ki of 188 nM against GalR1 and GalR2, resp.
IT **445453-46-3P 445454-93-3P 445454-95-5P**
445454-96-6P 445454-97-7P 445454-98-8P
445454-99-9P 445455-00-5P 445455-02-7P
445455-03-8P 445455-04-9P 445455-05-0P
445455-06-1P 445455-24-3P 445455-25-4P
445455-29-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine and indol-2-one derivs. as galanin GAL3 receptor antagonists for the treatment of depression and/or anxiety)
RN 445453-46-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(3-thienyl)-3-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 445454-93-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chloro-3-methylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-95-5 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-96-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-iodophenyl)imino]-1-(3-thienyl)-, (3Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-97-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-98-8 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-99-9 CAPLUS
CN 2H-Indol-2-one, 3-([1,1'-biphenyl]-4-ylimino)-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-00-5 CAPLUS
CN Benzoic acid, 3-[(Z)-[1,2-dihydro-2-oxo-1-(3-thienyl)-3H-indol-3-ylidene]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-02-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-phenoxyphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-03-8 CAPLUS
CN 2H-Indol-2-one, 3-[(4-bromophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-04-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-05-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methylphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-06-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dichlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-24-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[3-(1-methylethyl)phenyl]imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-25-4 CAPLUS
CN 2H-Indol-2-one, 3-[(4-cyclohexylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-29-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[[3-(trifluoromethyl)phenyl]imino]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **445455-58-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine and indol-2-one derivs. as galanin GAL3 receptor antagonists for the treatment of depression and/or anxiety)
RN 445455-58-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:594639 CAPLUS
DN 137:154941
TI Preparation of pyrimidine and indol-2-one derivatives as galanin GAL3 receptor antagonists for the treatment of depression and/or anxiety
IN Blackburn, Thomas P.; Konkel, Michael
PA Synaptic Pharmaceutical Corporation, USA
SO PCT Int. Appl., 832 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002060392	A2	20020808	WO 2002-US4608	20020131
	WO 2002060392	A3	20030925		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2438582	AA	20020808	CA 2002-2438582	20020131
	EP 1363638	A2	20031126	EP 2002-714918	20020131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1499970	A	20040526	CN 2002-807754	20020131
	JP 2004529089	T2	20040924	JP 2002-560588	20020131
	BR 2002006844	A	20050712	BR 2002-6844	20020131
	ZA 2003005686	A	20041025	ZA 2003-5686	20030723
	NO 2003003388	A	20030924	NO 2003-3388	20030729
	BG 108114	A	20050331	BG 2003-108114	20030820
PRAI	US 2001-775341	A	20010131		
	WO 2002-US4608	W	20020131		

OS MARPAT 137:154941
AB The title compds. [I (wherein W = H, halo, CN, etc.; X = substituted NH2, (un)substituted piperidino, 4-oxopiperidino, piperazino; R1 = bicyclic ring, adamantyl, (hetero)aryl, etc.; Y = substituted NH2, (un)substituted 2-isoquinolinyl, morpholino, etc.) and II (Y1-Y4 = H, alkyl, fluoroalkyl, etc.; A = (un)substituted Ph, thienyl, pyridylmethyl, etc.; B = (un)substituted Ph, pyridyl, indolyl, etc.)] which are selective antagonists for the GAL3 receptor, and are useful in treating depression and/or anxiety, were prepared Various general procedures for synthesis of the compds. I and II and their biol. data, were given. E.g., exemplified compound I [W = H; X = piperidino; Y = N-cyclohexyl-N-methylamino; R1 = 4-MeC6H4] showed Ki of 35 nM against GalR3 receptor binding vs. Ki of 668 nM and Ki of 188 nM against GalR1 and GalR2, resp.
IT **445453-46-3P 445454-93-3P 445454-95-5P**
445454-96-6P 445454-97-7P 445454-98-8P
445454-99-9P 445455-00-5P 445455-02-7P
445455-03-8P 445455-04-9P 445455-05-0P
445455-06-1P 445455-24-3P 445455-25-4P
445455-29-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine and indol-2-one derivs. as galanin GAL3 receptor antagonists for the treatment of depression and/or anxiety)

RN 445453-46-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(3-thienyl)-3-[[3-(trifluoromethyl)phenyl]imino]- (9CI) (CA INDEX NAME)



RN 445454-93-3 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chloro-3-methylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-95-5 CAPLUS
CN 2H-Indol-2-one, 3-[(4-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-96-6 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-iodophenyl)imino]-1-(3-thienyl)-, (3Z)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-97-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-,
(3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-98-8 CAPLUS
CN 2H-Indol-2-one, 3-[(3,5-difluorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-,
(3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445454-99-9 CAPLUS
CN 2H-Indol-2-one, 3-([1,1'-biphenyl]-4-ylimino)-1,3-dihydro-1-(3-thienyl)-,
(3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-00-5 CAPLUS
CN Benzoic acid, 3-[(Z)-[1,2-dihydro-2-oxo-1-(3-thienyl)-3H-indol-3-ylidene]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-02-7 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-phenoxyphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-03-8 CAPLUS
CN 2H-Indol-2-one, 3-[(4-bromophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-04-9 CAPLUS
CN 2H-Indol-2-one, 3-[(3-chlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-05-0 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(3-methylphenyl)imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-06-1 CAPLUS
CN 2H-Indol-2-one, 3-[(3,4-dichlorophenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-24-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[[3-(1-methylethyl)phenyl]imino]-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-25-4 CAPLUS
CN 2H-Indol-2-one, 3-[(4-cyclohexylphenyl)imino]-1,3-dihydro-1-(3-thienyl)-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 445455-29-8 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(tetrahydro-2H-pyran-4-yl)-3-[[3-(trifluoromethyl)phenyl]imino]-, (3Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT **445455-58-3P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine and indol-2-one derivs. as galanin GAL3 receptor antagonists for the treatment of depression and/or anxiety)
RN 445455-58-3 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-3-[(4-methylphenyl)imino]-1-(3-thienyl)-, (3E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1990:178540 CAPLUS
DN 112:178540
TI Synthesis and biological activities of new indole derivatives containing sulfide and/or sulfone moieties. Part I
AU El-Ezbawy, Samia R.; Abdel-Wahab, Aboel Magd A.
CS Fac. Sci., Assiut Univ., Assiut, Egypt
SO Phosphorus, Sulfur and Silicon and the Related Elements (1989), 44(3-4), 285-9
CODEN: PSSLEC; ISSN: 1042-6507
DT Journal
LA English
OS CASREACT 112:178540
AB 2,4,5-RR1R2C6H2XC6H4NH2-4 (R,R1 = H, NO2; R2 = NO2, Cl, Br, H; X = S, SO2) react with isatin, N-acetylisatin, isatin-N-Mannich bases, indole-3-carboxaldehyde and N-substituted indole-3-carboxaldehyde producing the corresponding indole derivs. I (R3 = H, MeCO) and II [R3 = H, 2,4-(O2N)2C6H3, 4-O2NC6H4CO]. A screen of these compds. for antibacterial activity showed most of the tested compds. possessed strong activity aganist a variety of bacteria.
IT **126592-73-2P 126592-74-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antibacterial activity of)
RN 126592-73-2 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[(2,5-dinitrophenyl)thio]phenyl]imino]-1,3-dihydro-1-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 126592-74-3 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[(5-chloro-2-nitrophenyl)thio]phenyl]imino]-1,3-dihydro-1-(4-morpholinyl)- (9CI) (CA INDEX NAME)



IT **126592-75-4P 126592-76-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 126592-75-4 CAPLUS
CN 2H-Indol-2-one, 3-[[4-[(5-bromo-2-nitrophenyl)thio]phenyl]imino]-1,3-dihydro-1-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 126592-76-5 CAPLUS
CN 2H-Indol-2-one, 1,3-dihydro-1-(4-morpholinyl)-3-[[4-[(4-nitrophenyl)thio]phenyl]imino]- (9CI) (CA INDEX NAME)



```
=> => d his

     (FILE 'HOME' ENTERED AT 18:55:59 ON 01 DEC 2005)

     FILE 'REGISTRY' ENTERED AT 18:56:04 ON 01 DEC 2005
L1             STRUCTURE UPLOADED
L2           5 S L1 SSS SAM
L3          40 S L1 SSS FUL

     FILE 'CAPLUS' ENTERED AT 18:57:01 ON 01 DEC 2005
L4          10 S L3

     FILE 'CAOLD' ENTERED AT 18:57:35 ON 01 DEC 2005

=> s l3
L5           0 L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY     SESSION
FULL ESTIMATED COST                                    0.43      212.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY     SESSION
CA SUBSCRIBER PRICE                                    0.00       -7.30

STN INTERNATIONAL LOGOFF AT 18:57:45 ON 01 DEC 2005
```